• History
• Mission
• Strategy
• Organization
• Key Activities

Key Activities

Key achievements 2009

• Zymenex devoted the company's Research and Development efforts to the recombinant enzyme, Lamazym, for treatment of the Lysosomal Storage Disease, Alpha-mannosidosis and the recombinant enzyme Galaczym for Krabbe disease.
• The EU 6th framework supported "Hue-Man" group with the title "Development Of An Effective Enzyme Replacement Therapy For Human Alpha-Mannosidosis" was completed in October 2009. The group consisted of laboratories from Germany, France, UK, Czech, Norway and Denmark, with Zymenex as the sole participating industrial partner. A Natural History Study in Alpha-Mannosidosis patients was performed, with the aim of elucidating the progression of the disease and pinpointing relevant clinical endpoints to use in the upcoming clinical trial.